Odonate Therapeutics Inc. (NASDAQ:ODT) traded today at a new 52-week low of $3.04. So far today approximately 3.1 million shares have been exchanged, as compared to an average 30-day volume of 1.6 million shares.
There is potential upside of 1.3% for shares of Odonate Therapeutics Inc. based on a current price of $3.42 and an average consensus analyst price target of $3.47.
Odonate Therapeutics Inc is a US-based pharmaceutical company that is engaged in the development of therapeutics which improves and extends the lives of patients with cancer. The company mainly focuses on the development of tesetaxel, a novel chemotherapy agent that belongs to a class of drugs, taxanes, which are widely used in the treatment of cancer including breast cancer. The key product of the company is Tesetaxel which is chemotherapy for oral administration with a low pill burden for various types of cancers.
Odonate Therapeutics Inc. share prices have moved between a 52-week high of $46.50 and the current low of $3.04 and are currently at $3.42 per share.
Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts
To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected
About InvestorBrandNetwork (IBN)
InvestorBrandNetwork (IBN) consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign.
For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer